title: Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma.
abstract: β-arrestin1 and NF-κB have been demonstrated to be associated with tumorigenesis, tumor progression, and metastasis. Thus far, there is nevertheless little study about these two molecules in lung adenocarcinoma. The aim of this study was to investigate the correlation between β-arrestin1 and NF-κB expression and the clinicopathological characteristics in lung adenocarcinoma. A total of 115 surgically resected lung adenocarcinoma patients were recruited for the study. Expression of β-arrestin1 and p65 were detected by immunohistochemistry (IHC) in lung adenocarcinoma tissue samples. Nuclear expression of β-arrestin1 and p65 were observed in 39.1 % (45/115) and 46.1 % (53/115) cases of lung adenocarcinoma, respectively. And high expression of β-arrestin1 had negative prognostic impact for overall survival (OS) and disease-free survival (DFS) (p = 0.034 and p = 0.033). In addition, overexpression of p65 indicated a significantly poor OS and DFS than those of lower-expression (p = 0.038 and p = 0.041). Furthermore, co-expression of nuclear β-arrestin1 and p65 correlated with poorer OS and DFS in lung adenocarcinoma patients. Multivariate analysis using the Cox regression model confirmed that co-expression of nuclear β-arrestin1 and p65 was an independent prognostic factor for tumor progression (p = 0.008). In conclusion, these data indicated that co-expression of nuclear β-arrestin1 and p65 was a novel predictor for worse prognosis in patients with lung adenocarcinoma.
authors.affiliation: Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021, People's Republic of China.
authors.forename: Jianyu
authors.initials: J
authors.lastname: Yu
authors.forename: Liguang
authors.initials: L
authors.lastname: Wang
authors.forename: Tiehong
authors.initials: T
authors.lastname: Zhang
authors.forename: Hongchang
authors.initials: H
authors.lastname: Shen
authors.forename: Wei
authors.initials: W
authors.lastname: Dong
authors.forename: Yang
authors.initials: Y
authors.lastname: Ni
authors.forename: Jiajun
authors.initials: J
authors.lastname: Du
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D019390:Arrestins / Q000096:biosynthesis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D063646:Carcinogenesis / Q000235:genetics; D002294:Carcinoma, Squamous Cell; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis* / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D051996:Transcription Factor RelA / Q000096:biosynthesis* / Q000235:genetics; D000071557:beta-Arrestins
chemical_list: D019390:Arrestins; D014408:Biomarkers, Tumor; D016328:NF-kappa B; D051996:Transcription Factor RelA; D000071557:beta-Arrestins
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98 (18):10386-91
references.pmid: 11517301
references.citation: Prog Mol Biol Transl Sci. 2013;118:395-411
references.pmid: 23764062
references.citation: EMBO J. 2014 Jun 17;33(12 ):1365-82
references.pmid: 24837709
references.citation: J Biol Chem. 2003 Mar 28;278(13):11648-53
references.pmid: 12538596
references.citation: Anticancer Res. 2004 Mar-Apr;24(2C):1071-5
references.pmid: 15154625
references.citation: Cancer. 2006 Dec 1;107(11):2637-46
references.pmid: 17078054
references.citation: J Biol Chem. 2002 Oct 4;277(40):37693-701
references.pmid: 12167659
references.citation: Nature. 2006 May 25;441(7092):431-6
references.pmid: 16724054
references.citation: J Biol Chem. 2012 Mar 16;287(12 ):8932-43
references.pmid: 22267743
references.citation: Oncogene. 2013 Oct 17;32(42):5066-77
references.pmid: 23208497
references.citation: Oncology. 2010;78(3-4):181-8
references.pmid: 20414006
references.citation: Annu Rev Immunol. 1998;16:225-60
references.pmid: 9597130
references.citation: J Natl Cancer Inst. 2011 Feb 16;103(4):317-33
references.pmid: 21212384
references.citation: Lung Cancer. 2014 Feb;83(2):189-96
references.pmid: 24355259
references.citation: Oncogene. 2014 May 22;33(21):2709-16
references.pmid: 23812430
references.citation: Oncology. 2013;85(2):86-94
references.pmid: 23860225
references.citation: Cell Cycle. 2006 Sep;5(18):2060-3
references.pmid: 16969081
references.citation: Nat Rev Immunol. 2005 Oct;5(10):749-59
references.pmid: 16175180
references.citation: Dis Esophagus. 2012 Nov-Dec;25(8):716-22
references.pmid: 22292507
references.citation: Mol Pharmacol. 2003 Aug;64(2):447-55
references.pmid: 12869650
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12011-6
references.pmid: 17620599
references.citation: Cell. 2009 Oct 30;139(3):535-46
references.pmid: 19879840
references.citation: Biochem J. 2009 Jan 1;417(1):287-96
references.pmid: 18729826
references.citation: Life Sci. 2014 Nov 24;118(2):179-84
references.pmid: 24530737
references.citation: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references.pmid: 20180029
references.citation: Nat Rev Cancer. 2002 Apr;2(4):301-10
references.pmid: 12001991
references.citation: Cell. 2005 Dec 2;123(5):833-47
references.pmid: 16325578
references.citation: Oncogene. 2012 Jan 19;31(3):282-92
references.pmid: 21685944
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1492-7
references.pmid: 16432186
references.citation: Mol Cancer Res. 2008 Mar;6(3):364-71
references.pmid: 18337446
references.citation: Science. 2002 Nov 8;298(5596):1241-5
references.pmid: 12424381
references.citation: Br J Cancer. 2007 Aug 20;97(4):523-30
references.pmid: 17622249
references.citation: Cancer Cell. 2004 Sep;6(3):203-8
references.pmid: 15380510
references.citation: Cancer. 2010 Jul 1;116(13):3276-84
references.pmid: 20564628
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23 ):8603-7
references.pmid: 15173580
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Nature. 2004 Sep 23;431(7007):461-6
references.pmid: 15329734
references.citation: Cell Cycle. 2010 Oct 1;9(19):4013-24
references.pmid: 20935513
references.citation: Nat Rev Drug Discov. 2004 Jan;3(1):17-26
references.pmid: 14708018
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5501-7
references.pmid: 15328189
references.citation: J Cell Sci. 2007 Jan 15;120(Pt 2):213-8
references.pmid: 17215450
references.citation: Cancer. 2008 May 15;112(10):2258-66
references.pmid: 18327814